We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published bySonia Leadingham
Modified over 2 years ago
© 2008 Universitair Ziekenhuis Gent1 ARIA-guidelines, an update Van Cauwenberge P, MD, PhD Van Hoecke H, MD Philippe Gevaert, MD, PhD Department of Otorinolaryngology Ghent University, Belgium
2 2© 2008 Universitair Ziekenhuis Gent Allergic rhinitis: treatment modalities From Diamant Z
3 3© 2008 Universitair Ziekenhuis Gent allergen avoidance indicated when possible allergen avoidance indicated when possible pharmacotherapy safety effectiveness easy to be administered pharmacotherapy safety effectiveness easy to be administered immunotherapy effectiveness specialist prescription may alter the natural course of the disease immunotherapy effectiveness specialist prescription may alter the natural course of the disease patient's education always indicated patient's education always indicated COSTS Cornerstones of AR treatment
4 4© 2008 Universitair Ziekenhuis Gent Clinical guidelines ‘Clinical guidelines are systematically developed statements to assist practioners and patients in making decisions about appropriate and effective health care in specific circumstances.’ Jackson R, et al. BMJ 1998
5 5© 2008 Universitair Ziekenhuis Gent , Opinion-based guidelines Evidence-based guidelines Guidelines for allergic rhinitis 2008
6 6© 2008 Universitair Ziekenhuis Gent Allergy 1994;49:1-34 V.J. Lund D. Aaronson J. Bousquet R. Dahl R.J. Davies S. Durham R. Gerth van Wijk K. Holmberg E. Juniper Ian S. Mackay L. Malm N. Mygind M. Okuda C. Ortolani H.M. Schanker S.L. Spector P. van Cauwenberge M.R. Wayoff International Consensus Report 1994
7 7© 2008 Universitair Ziekenhuis Gent Scan pag 28 International Consensus Report: Flow Chart
8 8© 2008 Universitair Ziekenhuis Gent D. Skoner M. Dykewicz S. Fineman R. Nicklas R. Lee J. Blessing-Moore Ann All Asthma Immunol 1998; 81: J. Li I. Bernstein W. Berger S. Spector D. Schuller American Guidelines on Rhinitis 1998
9 9© 2008 Universitair Ziekenhuis Gent P. van Cauwenberge C. Bachert J. Bousquet G. Canonica S. Durham W. Fokkens P. Howarth Allergy 2000;55: V Lund N. Mygind G. Passalacqua D. Passali G. Scadding D. Wang EAACI Position Paper 2000
10 © 2008 Universitair Ziekenhuis Gent Nasal Corticosteroids Inadeq. control Inadeq. control Inadeq. control Need for therapy ? Mild disease or occasional symptoms Moderate disease or long duration Severe disease Oral or Nasal Antihistamines (Cromones) Nasal Corticosteroids + Oral or Nasal Antihistamines Add further symptomatic treatment Short-course Oral Steroids Consider Immunotherapy For eye symptoms : topical antihistamines or cromones Seasonal allergic rhinitis
11 © 2008 Universitair Ziekenhuis Gent Perennial allergic rhinitis in adults Inadeq. control Need for therapy ? Avoidance Environment control Moderate disease or long duration Severe symptoms Oral or Nasal Antihistamines Nasal Corticosteroids Nasal Corticosteroids + Antihistamines Inadeq. control Further examinations Inadeq. control Mild disease or occasional symptoms
12 © 2008 Universitair Ziekenhuis Gent Perennial allergic rhinitis in adults If resistant RESISTANT CASES Resistant rhinorrhea Short Course of Topical Decongestants/ Oral Decongestants/ Oral Steroids Nasal Ipratropium bromide Immunotherapy Nasal blockage Surgical turbinate reduction
13 © 2008 Universitair Ziekenhuis Gent J. Bousquet P. van Cauwenberge N. Khaltaev N. Ait-Khaled I. Annesi-Maesano C. Bachert C. Baena-Cagnani E. Bateman S. Bonini G. Canonica K. Carlsen P. Demoly S. Durham D. Enarson W. Fokkens R. Gerth van Wijk P. Howarth N. Ivanova J. Kemp J. Klossek R. Lockey V. Lund I. MacKay H. Malling E. Meltzer N. Mygind M. Okuda R. Pawankar D. Price G. Scadding F. Simons A. Szczeklik E. Valovirta A. Vignola D. Wang J. Warner K. Weiss ARIA 2001 In collaboration with WHO JACI 2001;108 (Suppl 5):S147-S333
14 © 2008 Universitair Ziekenhuis Gent Patients with (persistent) AR should be evaluated for asthma Patients with (persistent) asthma should be evaluated for AR A combined strategy should be developed to treat co-existing diseases of the upper and lower airways Combined approach for AR and asthma
15 © 2008 Universitair Ziekenhuis Gent Changed classification for AR Moderate-severe one or more items. abnormal sleep. impairment of daily activities, sport, leisure. abnormal work and school. troublesome symptoms Persistent. > 4 days per week. and > 4 weeks Mild normal sleep & no impairment of daily activities, sport, leisure & normal work and school & no troublesome symptoms Intermittent. 4 days per week. or 4 weeks in untreated patients
16 © 2008 Universitair Ziekenhuis Gent Persistent33%Persistent33% Intermittent67%Intermittent67% N=1,265 subjects with physician-based diagnosis SAR: symptoms restricted to spring and/or summer N=1,265 subjects with physician-based diagnosis SAR: symptoms restricted to spring and/or summer PAR51%PAR51% SAR49%SAR49% SAR/PAR ARIA study step 1 (N=1,230) Prevalences are different Bauchau et al, Eur Respir J 2004
17 © 2008 Universitair Ziekenhuis Gent Classification of AR Patients in General Practice during Pollen Season N=804 subjects with GP-based diagnosis Van Hoecke et al, 2005 persistent Intermittent Mod/Sev 2% 9% 55% Mild 33%
18 © 2008 Universitair Ziekenhuis Gent Van Hoecke et al, 2005 NS N=351 subjects with GP-based diagnosis, responsible allergens confirmed by allergy testing Responsible Allergens in Persistent vs Intermittent AR
19 © 2008 Universitair Ziekenhuis Gent Symptom Severity in Persistent vs Intermittent AR N=804 subjects with GP-based diagnosis Van Hoecke et al, 2005 IntermittentPersistentp value Runny nose NS Blocked nose Itchy nose Sneezing NS Conjunctivitis Severity of each symptom is measured on a scale 1-4, expressed as % with score 3 or 4 - N=804 Headache Somnolence
20 © 2008 Universitair Ziekenhuis Gent Burden of Persistent Rhinitis N=804 subjects with GP-based diagnosis Van Hoecke et al, 2005 IntermittentPersistentp value NS NS <0.001 Impaired sleep Impaired activities/sports/leisure Impaired school/work Troublesome symptoms Moderate/severe AR % Allergy testing <0.001 Specialist referral
21 © 2008 Universitair Ziekenhuis Gent Persistent AR Has Specific Clinical Characteristics T5SS (from 0 to 15): 8.97 (2.27)* RQLQ (from 0 to 6): 3.04 (0.93)* Loss of 17.9 work days per patient per year ** On co-morbidity = asthma, sinusitis, otitis media, upper respiratory infections: 11.8 events per month per 100 patients ** 10% mild vs 90% moderate Severe allergic rhinitis: Mild –moderate –severe subgroups? Validation ARIA
22 © 2008 Universitair Ziekenhuis Gent Ia Evidence from meta-analysis of randomised controlled trials Ib Evidence from at least one randomised controlled trial IIaEvidence from at least one controlled study without randomisation IIbEvidence from at least one other type of quasi-experimental study IIIEvidence from non-experimental descriptive studies, such as comparative studies, correlation studies and case-control studies IVEvidence from expert committee reports or opinions or clinical experience of respected authorities, or both A B C D Shekelle et al, BMJ 1999 Evidence-based recommendations
23 © 2008 Universitair Ziekenhuis Gent Strength of evidence for rhinitis treatments InterventionSAR Adult SAR Children PAR Adult PAR Children Oral anti-H1AAAA Nasal anti-H1AAAA Nasal CSAAAA Nasal cromoneAAAA AntileukotrieneAA Subcut SITAAAA Subling/nasal ITAAA Allergen avoidanceDDDD
24 © 2008 Universitair Ziekenhuis Gent mild intermittent mild persistent moderate severe intermittent moderate severe persistent allergen and irritant avoidance immunotherapy intra-nasal decongestant (<10 days) or oral decongestant local cromone intra-nasal steroid oral or local non-sedative H1-blocker Stepwise rhinitis treatment
25 © 2008 Universitair Ziekenhuis Gent ARIA 2008 In collaboration with WHO, Ga2len and AllerGen Allergy 2008; 63(Suppl 86):8-160 J. Bousquet N. Khaltaev A. Cruz J. Denburg W. Fokkens A. Togias T. Zuberbier C. Baena-Cagnani G. Canonica C. van Weel I. Agache N. Khaled C. Bachert M. Blaiss S. Bonini L. Boulet P. Bousquet P. Camargos K. Carlsen Y. Chen A. Custovic B. Dahl P. Demoly H. Douagui S. Durham R. Gerth van Wijk O. Kalayci M. Kaliner Y. Kim M. Kowalski P. Kuna L. Le C. Lemiere J. Li R. Lockey S. Mavale-Manuel E. Meltzer Y. Mohammad J. Mullol R. Naclerio R. Hehir K. Ohta S. Ouedraogo S. Palkonen N. Papadopoulos G. Passalacqua R. Pawankar T. A. Popov K.Rabe J. Rosado-Pinto G. Scadding F. Simons E. Toskala E. Valovirta P. Van Cauwenberge D.-Y. Wang M. Wickman B. Yawn A. Yorgancioglu A. Yusuf A. Zar
26 © 2008 Universitair Ziekenhuis Gent International Consensus 1994 EAACI 2000ARIA 2001ARIA 2008 Nr of members (should be between 6 & 15 (Shekelle, 1999) (18) OK (14) (37) (61) + 35 reviewers Composition of group ENT-All: OK No GP’s ENT-All: OK No GP’s OK Countries Continents3245 Gender (M/F)16/212/230/746/15 University vs non-university 16/214/0 34/353/8 Conflict of interest (pharmaceutical industry) Not mentioned Not mentioned Not specified who Specified Expert panel for guideline development
27 © 2008 Universitair Ziekenhuis Gent Need for ARIA update Increasing knowledge on epidemiology, diagnosis, management and comorbidities of AR since 1999 Need for validation of ARIA classification and management recommendations Availability of new evidence-based systems to guide recommendations, including safety, costs and efficacy of treatments Need to address previous gaps in knowledge (e.g. complementary and alternative medicine) 2008 Update
28 © 2008 Universitair Ziekenhuis Gent Strength of evidence for rhinitis treatments InterventionSAR Adult SAR Children PAR Adult PAR Children PER Oral anti-H1AAAAA Nasal anti-H1AAAAA* Nasal GCSAAAAA* Nasal cromoneAAAAA* AntileukotrieneAA (>6y)AAA* Subcut SITAAAA Sublingual SITAAAA Anti-IgEAA (>12y)AA HomeopathyDDDD AccupunctureDDDD PhytotherapyBDDD Allergen avoidanceDDDD 2008 Update Indirect evidence*
29 © 2008 Universitair Ziekenhuis Gent mild intermittent mild persistent moderate severe intermittent moderate severe persistent allergen and irritant avoidance immunotherapy intra-nasal decongestant (<10 days) or oral decongestant local cromone intra-nasal steroid oral or local non-sedative H1-blocker or anti-leukotriene Stepwise rhinitis treatment 2008 Update
30 © 2008 Universitair Ziekenhuis Gent MeasureEvidence of effect on allergen levelsEvidence of clinical benefit HOUSE DUST MITES Encase bedding in impermeable coversSome None (adults): Evidence A Some (children): Evidence B Wash bedding on a hot cycle (55–60°C)SomeNone: Evidence A Replace carpets with hard flooringSomeNone: evidence A Acaricides and/or tannic acidWeakNone: Evidence A Minimize objects that accumulate dustNoneNone: Evidence B Use vacuum cleaners with integral HEPA filter and double- thickness bags WeakNone: Evidence B Remove, hot wash or freeze soft toysNoneNone: Evidence B PETS Remove cat/dog from the homeWeakNone: Evidence B Keep pet from main living areas/bedroomsWeakNone: Evidence B Use HEPA-filter air cleanersSomeNone: Evidence B Wash petWeakNone: Evidence B Replace carpets with hard flooringNoneNone: Evidence B Use vacuum cleaners with integral HEPA filter and double- thickness bags NoneNone: Evidence B SET OF ALLERGEN CONTROL MEASURES SomeSome: Evidence B Effectiveness of avoidance measures in rhinitis and asthma for certain indoor allergens
31 © 2008 Universitair Ziekenhuis Gent Validation of guidelines Treat patients according to guidelines to usual practice Investigators randomised to: 225 patients with SAR 244 patients with SARscreened and enrolled Patients treated for 3 weeks Recorded: –Reflective symptoms twice daily –Medicine utilisation daily –RQLQ and SF-36 at day 7 and day 20 –Global evaluation at day 21 AB Bousquet J, van Cauwenberge P, Lund V Allergy 2003
32 © 2008 Universitair Ziekenhuis Gent Benefits of a guided strategy Bousquet J, van Cauwenberge P, Lund V Allergy 2003
33 © 2008 Universitair Ziekenhuis Gent Dissemination of ARIA guidelines Have you heard about ARIA?
34 © 2008 Universitair Ziekenhuis Gent Implementation of ARIA guidelines Mild intermittent (n=69) Mild persistent (n=17) Mod/sev intermittent (n=445) Mod/sev persistent (n=273) Treated according to ARIA 56,5%64,7%45,4%63,0% Undertreated10,1%0%2,9%30,4% Overtreated33,3%35,3%51,7%6,6% Treatment prescribed by 95 Belgian GPs in 804 AR patients Van Hoecke H, Van Cauwenberge P, Allergy 2006
35 © 2008 Universitair Ziekenhuis Gent Rhinitis treatment improves asthma EVIDENCE A ++Anti-IgE mAb Immunotherapy Leucotriene modifiers Nasal GCS +Antihistamines Revised GINA 2006: Rhinitis treatment
36 © 2008 Universitair Ziekenhuis Gent Conclusion Aim of guidelines is to improve patient care and to support physicians by informing them and by improving their decisions Benefits of a guided strategy have been validated Several barriers to put guidelines into practice More efforts are needed to adapt guidelines to the needs of the end-users
ARIA QUIDELINES ON MANAGEMENT OF ALLERGIC RHINITIS MSD Be well.
C A SHINKWIN BON SECOURS GP STUDY DAY 28 JANUARY, 2012.
Rhinitis April 10, THE NOSE CT of THE NOSE.
WEEK 1 You have 10 seconds to name…
Addition 1’s to
Allergic rhinitis in children Dr Gulamabbas Khakoo Consultant in Paediatrics, Hillingdon Hospital NHS Trust Consultant in Paediatric Allergy St Mary’s.
Addition Facts = = =
Decreasing the burden of allergy Brigita Sitkauskiene, MD, PhD EAACI Member-at-Large Associate Professor and Head Division for Allergology and Clinical.
Hayfever Darrelle. AKT A 30-year-old man presents with sneezing, nasal blockage and a constant runny nose. Which one of the following does not have.
Gerard Kelly MD MEd FRCS (ORL-HNS) FRCS (Ed) ENT surgeon, Leeds 6 th March 2014, Leeds Masonic Hall ENT The Leeds Teaching Hospitals NHS Trust and general.
Allergic Rhinitis Richard Douglas. Prevalence Most common disease 20% adult population.
Management of Rhinitis in Patients with Asthma Michael Schatz, MD, MS Chief, Department of Allergy Kaiser Permanente, San Diego, CA.
Break Time Remaining 10:00. Break Time Remaining 9:59.
SUBTRACTING INTEGERS 1. CHANGE THE SUBTRACTION SIGN TO ADDITION 2. TAKE THE INVERSE OF THE SECOND NUMBER 3. FOLLOW THE RULES FOR ADDITION 4. ADD THE OPPOSITE.
TWO STEP EQUATIONS 1. SOLVE FOR X 3. DIVIDE BY THE NUMBER IN FRONT OF THE VARIABLE 2. DO THE ADDITION STEP FIRST.
13:00 Clock will move after 1 minute PPT – VCIC Timer 15.ppt.
Management of Allergic Rhinitis Dr Rubaiyat Haque Consultant Allergist.
CALENDAR NEW CALENDAR
Adding Up In Chunks. Category 1 Adding multiples of ten to any number.
Joint Non-Prescription Drugs and Pediatric Advisory Committee Meeting October 18-19, 2007 Considerations for Extrapolation of Efficacy from Adults to Children.
Copyright © Action Works 2008 All Rights Reserved - Photos by David D. Kempster 1.
3 : 00 2 : 59 2 : 58 2 : 57 2 : 56 2 : 55 2 : 54.
Copyright © 2012, Elsevier Inc. All rights Reserved. 1 Chapter 7 Modeling Structure with Blocks.
Subtraction: Adding UP. Category 1 The whole is a multiple of ten.
Allergy Symptom Response Following Conversion from Injection Immunotherapy to Sublingual Immunotherapy CDR Timothy Clenney, MD, MPH Naval Medical Center.
1 STANDARD 1.3 Converting a Fraction to % Problem 1 Problem 4 Problems 3 Problem 2 Problem 5 END SHOW PRESENTATION CREATED BY SIMON PEREZ. All rights reserved.
5 minutes 4 minutes 3 minutes 2 : 00 1 : 59 1 : 58.
Bulgaria Ewopharma MedReps Training Course 14 December 2010.
MULT. INTEGERS 1. IF THE SIGNS ARE THE SAME THE ANSWER IS POSITIVE 2. IF THE SIGNS ARE DIFFERENT THE ANSWER IS NEGATIVE.
×1= 9 4 1×1= 1 5 8×1= 8 6 7×1= 7 7 8×3= 24.
PP Test Review Sections 6-1 to 6-6 Mrs. Rivas 1. 2.
DLMSO Classroom Timer Select a time to count down from the clock above 60 min 45 min 30 min 20 min 15 min 10 min 5 min or less.
Allergen Immunotherapy: From Shots to Tablets Susan Waserman MSc MDCM FRCPC Professor of Medicine Division of Clinical Allergy and Immunology Life and.
Asthma Management Fine Tuning Maximum control with minimum medication Start with mild asthma and work up the scale (BTS/SIGN 2004)
© 2008 Universitair Ziekenhuis Gent1 ANTIMICROBIAL PROPHYLAXIS FOR SURGERY IN PATIENTS WITH PENICILLIN ALLERGY Dirk VOGELAERS Department of General Internal.
Component 1: Measures of Assessment and Monitoring n Two aspects: –Initial assessment and diagnosis of asthma –Periodic assessment and monitoring.
Clinical process for properly prescribe allergen immunotherapy Noel Rodriguez-Perez, MD Professor of pediatrics, Allergy& Immunology State University of.
Dr muaid I. Aziz FIMCS. Definition: its an inflammation of the lining of the nose characterized by two or more of the following symptoms nasal obstruction.
Jeopardy Topic 1Topic Q 1Q 6Q 11Q 16Q 21 Q 2Q 7Q 12Q 17Q 22 Q 3Q 8Q 13Q 18Q 23 Q 4Q 9Q 14Q 19Q 24 Q 5Q 10Q 15Q 20Q 25 Final Jeopardy.
Performance of Hedges & Long Futures Positions in CBOT Corn Goodland, Kansas March 2, 2009 Daniel OBrien, Extension Ag Economist K-State Research and Extension.
BMU - E I 1 Development of renewable energy sources in Germany in
©2004 by Pearson Education11-1 R.C. Hibbeler Resistência dos Materiais, 5ª ed. 11 – Projetos de Vigas e Eixos.
HIV and Aging Kathleen K Casey, MD Director, AIDS Ambulatory Care Center Jersey Shore University Medical Center.
GARD Global Alliance against Chronic Respiratory Diseases WHO J Bousquet, R Dahl, N Khaltaev, HJ Bekedam.
The Rising Global Burden of Allergic Diseases and Asthma WORLD ALLERGY WEEK 2012.
Who should receive early anti-TNF therapy: With what benefits and risks? Ted Denson, MD Cincinnati Childrens Hospital Medical Center University of Cincinnati.
Treatment of Sleep Associate disturbance in Allergy Diseases Timothy J. Craig Professor of Medicine and Pediatrics Distinguished Educator Penn State University.
© 2017 SlidePlayer.com Inc. All rights reserved.